{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:14Z","timestamp":1789609214892,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T00:00:00Z","timestamp":1409702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Studies of pemphigus vulgaris and foliaceus patients treated with rituximab have used several different dosing protocols. Likewise, patients' clinical history varies in the length of the disease prior to initiation of rituximab, previous immunosuppressants used and adjuvants used during rituximab treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We sought to assess clinical factors associated with improved outcomes and a greater duration from last dose of rituximab to time of relapse in patients responding to a single cycle of rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively evaluated published cases of pemphigus patients treated with a single cycle of rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and fifty\u2010five patients were evaluated. An increased number of months with disease before receiving treatment were associated with failure to achieve complete remission. Patients treated using the low\u2010dose rheumatoid arthritis protocol (2\u00a0\u00d7\u00a0500\u00a0mg) experienced a lower rate of complete response and a decrease in the time to relapse. Patients treated using the standard lymphoma protocol (375\u00a0mg\/m<jats:sup>2<\/jats:sup>\u00a0\u00d7\u00a04\u00a0weeks) demonstrated improved time to relapse. There was no difference seen in the rate of patients reaching complete response in patients treated with the standard lymphoma protocol vs. the standard rheumatoid arthritis protocol (1000\u00a0mg\u00a0\u00d7\u00a02). The use of adjuvant plasma exchange or immunoadsorption was associated with an increase in the time to relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on these observations, the low\u2010dose rheumatoid arthritis protocol should not be recommended due to the inferior clinical response and shortened time to relapse.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12678","type":"journal-article","created":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T10:10:02Z","timestamp":1409739002000},"page":"777-782","source":"Crossref","is-referenced-by-count":55,"title":["An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab"],"prefix":"10.1111","volume":"29","author":[{"given":"K.T.","family":"Amber","sequence":"first","affiliation":[{"name":"Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hertl","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Philipps\u2010Universit\u00e4t Marburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,3]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.05.024"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-012-0017-3"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062930"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067752"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10411.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701286110"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06651.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2005.tb00862.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12080"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.8.1033"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005166"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.08.021"},{"key":"e_1_2_5_15_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2340\/00015555-0007","article-title":"Long\u2010lasting remission of pemphigus vulgaris treated with rituximab","volume":"86","author":"Esposito M","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07800.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05209_10.x"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10663.x"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04391.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.032"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-013-1355-4"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.1522"},{"key":"e_1_2_5_23_1","first-page":"335","article-title":"Rituximab therapy in severe juvenile pemphigus vulgaris","volume":"80","author":"Mamelak AJ","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000099591"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04192.x"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.06.007"},{"key":"e_1_2_5_27_1","first-page":"266","article-title":"Delayed response of oral pemphigus vulgaris to rituximab treatment","volume":"16","author":"Niedermeier A","year":"2006","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.12.019"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06740.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08358.x"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2008.00194.x"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20131990"},{"key":"e_1_2_5_33_1","first-page":"ELT24","article-title":"Anti\u2010CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory Pemphigus vulgaris: report of a case","volume":"88","author":"Virgolini L","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_5_34_1","first-page":"185","article-title":"Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants","volume":"85","author":"Wenzel J","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12972"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10732.x"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000187431"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12678","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12678","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:24:10Z","timestamp":1695471850000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,3]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/jdv.12678"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12678","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,3]]}}}